170 related articles for article (PubMed ID: 7829249)
1. Photosensitizing efficacy of MTHPC-PDT compared to photofrin-PDT in the RIF1 mouse tumour and normal skin.
van Geel IP; Oppelaar H; Oussoren YG; van der Valk MA; Stewart FA
Int J Cancer; 1995 Jan; 60(3):388-94. PubMed ID: 7829249
[TBL] [Abstract][Full Text] [Related]
2. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC.
van Geel IP; Oppelaar H; Marijnissen JP; Stewart FA
Radiat Res; 1996 May; 145(5):602-9. PubMed ID: 8619026
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.
van Geel IP; Oppelaar H; Oussoren YG; Schuitmaker JJ; Stewart FA
Br J Cancer; 1995 Aug; 72(2):344-50. PubMed ID: 7640216
[TBL] [Abstract][Full Text] [Related]
4. Does tumour uptake of Foscan determine PDT efficacy?
Veenhuizen R; Oppelaar H; Ruevekamp M; Schellens J; Dalesio O; Stewart F
Int J Cancer; 1997 Oct; 73(2):236-9. PubMed ID: 9335449
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study.
Baas P; van Geel IP; Oppelaar H; Meyer M; Beynen JH; van Zandwijk N; Stewart FA
Br J Cancer; 1996 Apr; 73(8):945-51. PubMed ID: 8611430
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy for gastrointestinal tumors using three photosensitizers--ALA induced PPIX, Photofrin and MTHPC. A pilot study.
Mĺkvy P; Messmann H; Regula J; Conio M; Pauer M; Millson CE; MacRobert AJ; Bown SG
Neoplasma; 1998; 45(3):157-61. PubMed ID: 9717528
[TBL] [Abstract][Full Text] [Related]
7. Foscan uptake and tissue distribution in relation to photodynamic efficacy.
Cramers P; Ruevekamp M; Oppelaar H; Dalesio O; Baas P; Stewart FA
Br J Cancer; 2003 Jan; 88(2):283-90. PubMed ID: 12610515
[TBL] [Abstract][Full Text] [Related]
8. Preclinical comparison of mTHPC and verteporfin for intracavitary photodynamic therapy of malignant pleural mesothelioma.
Opitz I; Krueger T; Pan Y; Altermatt HJ; Wagnières G; Ris HB
Eur Surg Res; 2006; 38(3):333-9. PubMed ID: 16785733
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic effects of combination photosensitization by hypericin, meso-tetrahydroxyphenylchlorin (mTHPC) and photofrin II on Staphylococcus aureus.
Kubin A; Wierrani F; Jindra RH; Loew HG; Grünberger W; Ebermann R; Alth G
Drugs Exp Clin Res; 1999; 25(1):13-21. PubMed ID: 10337500
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model.
Rovers JP; Saarnak AE; Molina A; Schuitmaker JJ; Sterenborg HJ; Terpstra OT
Br J Cancer; 1999 Oct; 81(4):600-8. PubMed ID: 10574244
[TBL] [Abstract][Full Text] [Related]
11. Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response.
Triesscheijn M; Ruevekamp M; Aalders M; Baas P; Stewart FA
Photochem Photobiol; 2005; 81(5):1161-7. PubMed ID: 15934792
[TBL] [Abstract][Full Text] [Related]
12. Phthalocyanine photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression.
Anderson C; Hrabovsky S; McKinley Y; Tubesing K; Tang HP; Dunbar R; Mukhtar H; Elmets CA
Photochem Photobiol; 1997 May; 65(5):895-901. PubMed ID: 9155263
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin.
Wagnieres G; Hadjur C; Grosjean P; Braichotte D; Savary JF; Monnier P; van den Bergh H
Photochem Photobiol; 1998 Sep; 68(3):382-7. PubMed ID: 9747593
[TBL] [Abstract][Full Text] [Related]
14. A comparison of functional bladder damage after intravesical photodynamic therapy with three different photosensitizers.
Post JG; te Poele JA; Schuitmaker JJ; Stewart FA
Photochem Photobiol; 1996 Mar; 63(3):314-21. PubMed ID: 8881337
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.
Schouwink H; Ruevekamp M; Oppelaar H; van Veen R; Baas P; Stewart FA
Photochem Photobiol; 2001 Apr; 73(4):410-7. PubMed ID: 11332037
[TBL] [Abstract][Full Text] [Related]
16. Foscan-mediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies.
Veenhuizen RB; Ruevekamp MC; Oppelaar H; Helmerhorst TJ; Kenemans P; Stewart FA
Int J Cancer; 1997 Oct; 73(2):230-5. PubMed ID: 9335448
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term normal tissue damage with photodynamic therapy in pig trachea: a fluence-response pilot study comparing Photofrin and mTHPC.
Murrer LH; Hebeda KM; Marijnissen JP; Star WM
Br J Cancer; 1999 May; 80(5-6):744-55. PubMed ID: 10360652
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vivo efficiency of photofrin II-, mTHPC-, mTHPC-PEG- and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma.
Reuther T; Kübler AC; Zillmann U; Flechtenmacher C; Sinn H
Lasers Surg Med; 2001; 29(4):314-22. PubMed ID: 11746108
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®)).
Kniebühler G; Pongratz T; Betz CS; Göke B; Sroka R; Stepp H; Schirra J
Photodiagnosis Photodyn Ther; 2013 Sep; 10(3):220-8. PubMed ID: 23993847
[TBL] [Abstract][Full Text] [Related]
20. mTHPC mediated, systemic photodynamic therapy (PDT) for nonmelanoma skin cancers: Case and literature review.
Horlings RK; Terra JB; Witjes MJ
Lasers Surg Med; 2015 Dec; 47(10):779-87. PubMed ID: 26462858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
